Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia
Authors:
- Simon ZhornitskySimon Zhornitsky
- Emmanuel StipESEmmanuel Stip
- Tania PampoulovaTPTania Pampoulova
- Élie RizkallahÉRÉlie Rizkallah
- Jean‐Pierre ChiassonJCJean‐Pierre Chiasson
- Stéphane PotvinSPStéphane Potvin
- 28 July 2010
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 25 (13) , 2188-2194
Abstract
Extrapyramidal symptoms (EPS) such as parkinsonism, dystonia, dyskinesia, and akathisia are conditions of impaired motor function, which are associated with chronic antipsychotic treatment in schizophrenia. In addition, EPS is often exacerbated by psychoactive substance (PAS) abuse, which is frequently observed in this population. Few studies, however, have investigated the contribution of PAS abuse on EPS in PAS‐abusers without comorbid psychosis. This study compared the occurrence of EPS in outpatient schizophrenia patients with (DD group; n= 36) and without PAS abuse (SCZ group; n = 41) as well as in nonschizophrenia PAS abusers undergoing detoxification [substance use disorder (SUD) group; n = 38]. Psychiatric symptoms were measured using the Positive and Negative Syndrome Scale and the Calgary Depression Scale for schizophrenia. Extrapyramidal symptoms were evaluated with the Extrapyramidal Symptoms Rating Scale and the Barnes Akathisia Scale. SUD diagnoses were complemented with urine drug screenings. We found that DD patients exhibited significantly more parkinsonism than SCZ patients. Our subanalyses revealed that cocaine and alcohol abuse/dependence was responsible for the increase in parkinsonism in DD patients. Additionally, we found that SUD individuals exhibited significantly more akathisia than SCZ patients. In these latter individuals, subanalyses revealed that alcohol and cannabis abuse/dependence was responsible for the increase in akathisia. Our results suggest that PAS abuse is a contributor to EPS in individuals with and without schizophrenia. © 2010 Movement Disorder Society.Keywords
This publication has 54 references indexed in Scilit:
- The Expert Consensus Guideline SeriesThe Journal of Clinical Psychiatry, 2009
- Partial compliance in schizophrenia and the impact on patient outcomesPsychiatry Research, 2008
- The Burden of Mental DisordersEpidemiologic Reviews, 2008
- Encyclopedia of Molecular Pharmacology2008
- Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophreniaPsychopharmacology, 2005
- Subjective Experience and Dopamine D2 Receptor Occupancy in Patients Treated with Antipsychotics: Clinical ImplicationsThe Canadian Journal of Psychiatry, 2004
- Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidolPsychopharmacology, 2002
- Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)BMC Psychiatry, 2001
- The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A pet studyLife Sciences, 1995
- Comorbidity of Mental Disorders With Alcohol and Other Drug AbuseJAMA, 1990